|
JULY 18th, 2005
NutraCea Announces Natural Treatment for Arthritic Conditions
NutraCea (OTC:NTRZ) (BULLETIN BOARD: NTRZ) is bringing its FlexProtex COX-2 inhibitor product
to market via an infomercial campaign to be broadcast on ITV Direct. The new product is for the treatment of arthritis and
joint inflammation. The infomercial is scheduled to air in the United States on ITV direct on July 21, 2005.
FlexProtex is based on stabilized rice bran derivatives and other
ingredients known as natural COX-2 inhibitors. The company indicates that the mechanism of COX-2 inhibition is also the basis
for a number of pharmaceutical drugs.
Patricia McPeak, Founder and CEO of NutraCea, gave her reasons for
the selection of ITV as the market avenue, "We selected ITV Direct because of their historical success in bringing dietary
supplements to market and to introduce our novel stabilized rice bran products, such as FlexProtext, to the entire nation.
Backed by many years of research and patents, which give us a unique positioning in the marketplace, we're very proud to be
able to offer such high quality products at very reasonable prices by using the medium of direct-to-consumer selling."
NutraCea is focused on the development of nutraceuticals for natural
arthritic relief and the lowering of cholesterol and all-natural "cosmeceutical" beauty aids. The company has also has a
low-cost nutrition product, based on rice straw, that has potential to feed the world’s malnourished.
JUNE 24th, 2005
Martin Nutraceuticals Inc. (Pink Sheets:MTNU) has suggested
that women suffering from arthritis take a closer look at Arthrizyme as an alternative to Ibuprofen. Ibuprofen, the company
notes, has been linked as a source of breast cancer. The company took the following quote from the Journal of the National
Cancer Institute in support of its claim, "1,500 women who have been taking Ibuprofen for 5 years or more, are at an increased
risk of breast cancer by 51%."
Dr. Martin, Director of Research and Product Development at Martin
Nutraceuticals Inc. commented on the bad news about Ibuprofen, "These results ought to scare the life out of arthritic patients
on Ibuprofen. With the use of Celebrex and Vioxx also causing great concern, the market is looking for a safe alternative
that is highly effective. The answer is found in Arthrizyme, the all natural patent-pending systemic oral enzyme formula developed
by Martin Nutraceuticals Inc."
Martin Nutraceuticals notes that Arthrizyme operates through the
breakdown of harmful protein and that 1 out of 3 Americans have some form of arthritis.
JUNE 2nd, 2005
Protalex Raises $5.1 Million - Rheumatoid Arthritis, Pemphigus
Protalex, Inc. (OTC:PRTX) (BULLETIN BOARD: PRTX) has raised, through a private placement of
common stock and warrants, approximately $5.1 million . The company has been developing a new class of drugs for the treatment
of Rheumatoid Arthritis, Pemphigus and other autoimmune diseases.
Steven H. Kane, President and CEO of Protalex, gave an indication
of how the funds would be spent, "The Company will use the proceeds of the private placement primarily to finance the upcoming
Phase I clinical trials for its lead compound, PRTX-100, in Rheumatoid Arthritis and Pemphigus and general working capital
purposes."
MAY 26th, 2005
Phenomix Corporation with a new round of $40 million in Series B
funding, brings its total level of funding up to $65.5 million. The drug discovery company, which is focused on oral alternative
treatments as opposed to the traditional injectable treatments, presently has under development therapies for type 2 diabetes
and rheumatoid arthritis.
Primary investors in the round included JPMorgan Partners and Delphi
Ventures as well as Baker Brothers Investments Alta Partners, Sofinnova Ventures, Bay City Capital, CMEA Ventures, GBS Venture
Partners and Novartis BioVenture Fund.
|
